Jack Phillips Sells 26,545 Shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Stock

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Jack Phillips sold 26,545 shares of the business’s stock in a transaction on Friday, April 12th. The stock was sold at an average price of $0.86, for a total transaction of $22,828.70. Following the completion of the sale, the chief executive officer now directly owns 129,726 shares in the company, valued at approximately $111,564.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Jack Phillips also recently made the following trade(s):

• On Wednesday, April 17th, Jack Phillips sold 26,735 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $0.78, for a total transaction of $20,853.30.
• On Thursday, April 4th, Jack Phillips sold 15,887 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $0.88, for a total transaction of $13,980.56.
• On Thursday, February 1st, Jack Phillips sold 494 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $1.30, for a total transaction of $642.20.

Accelerate Diagnostics Trading Up 11.6 %

NASDAQ AXDX opened at $0.86 on Friday. The firm’s fifty day moving average price is $0.99 and its two-hundred day moving average price is $3.16. Accelerate Diagnostics, Inc. has a 1 year low of $0.73 and a 1 year high of $11.90. The firm has a market capitalization of $18.61 million, a P/E ratio of -0.18 and a beta of 0.52.

Institutional Trading of Accelerate Diagnostics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Swiss National Bank increased its holdings in shares of Accelerate Diagnostics by 19.0% in the first quarter. Swiss National Bank now owns 85,300 shares of the medical research company’s stock valued at $123,000 after purchasing an additional 13,600 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Accelerate Diagnostics by 17.9% in the first quarter. JPMorgan Chase & Co. now owns 418,359 shares of the medical research company’s stock valued at $602,000 after purchasing an additional 63,513 shares during the last quarter. HighTower Advisors LLC increased its holdings in shares of Accelerate Diagnostics by 115.6% in the first quarter. HighTower Advisors LLC now owns 37,302 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 20,000 shares during the last quarter. Bank of Montreal Can acquired a new position in shares of Accelerate Diagnostics in the first quarter valued at $27,000. Finally, Baird Financial Group Inc. increased its holdings in shares of Accelerate Diagnostics by 15.5% in the first quarter. Baird Financial Group Inc. now owns 1,741,547 shares of the medical research company’s stock valued at $2,508,000 after purchasing an additional 233,478 shares during the last quarter. 17.14% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

AXDX has been the topic of a number of research reports. StockNews.com initiated coverage on shares of Accelerate Diagnostics in a research report on Saturday. They issued a “hold” rating on the stock. Craig Hallum dropped their price target on shares of Accelerate Diagnostics from $2.00 to $1.00 and set a “hold” rating on the stock in a research report on Monday, April 1st. Finally, William Blair reaffirmed an “outperform” rating on shares of Accelerate Diagnostics in a research report on Tuesday, April 2nd.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.